Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY20 results · Apr–Jun 2019
Sun Pharma Advanced Research Company reported revenue from operations of ₹17.32 crore (up 3.0% from Q1 FY19) and net loss of ₹94.19 crore for Q1 FY20 (Apr–Jun 2019), on a standalone basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 17.32 | 16.81 | +3.0% | 84.83 | −79.6% |
| Other income | 3.67 | 1.23 | +198.4% | 4.43 | −17.2% |
| Total income | 20.99 | 18.04 | +16.4% | 89.26 | −76.5% |
| Profit before tax | (94.19) | (64.48) | Loss widened | (9.35) | Loss widened |
| Net profit for the period | (94.19) | (64.48) | Loss widened | (9.35) | Loss widened |
| EPS, basic (₹) | (3.59) | (2.57) | Loss widened | (0.37) | Loss widened |
| Net margin (%) | -543.8 | -383.6 | -11.0 |
Standalone
- Filed with BSE
- 30 Jul 2019, 14:42 IST
- Board meeting
- 29 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE